Demographic, laboratory and imaging characteristics of 55 patients with acute ischaemic stroke receiving IVT with tissue plasminogen activator
| N | Reference | Age and gender | Dabigatran | aPTT | IVT | NIHSS | Vessel occluded | mRS | ICH | Adverse events | Recommended anticoagulation | ||||||||
| Dose (mg) | Last intake (min) | Serum concentration | Time to rtPA | rtPA dose | Admission | Outcome | Variation | Pre-stroke | At admission | At follow-up | |||||||||
| 1 | 4 | 88 | F | 220 | 270 | 202.4 | 71 | 160 | 0.9 | 10 | 1 | 9 | NA | NA | NA | NA | NA | No | Apixaban |
| 2 | 4 | 67 | M | 300 | 338 | 183.7 | 77 | 247 | 0.9 | 4 | 0 | 4 | NA | NA | NA | NA | NA | No | DAB |
| 3 | 4 | 84 | M | 300 | 424 | 31.4 | 84 | 133 | 0.9 | 10 | 2 | 8 | NA | NA | NA | NA | NA | Urinary infection | DAB |
| 4 | 4 | 85 | M | 220 | NA | 43 | 36 | 95 | 0.9 | 7 | 2 | 5 | NA | NA | NA | NA | NA | No | DAB |
| 5 | 4 | 82 | M | 220 | NA | 172.2 | 52 | 123 | 0.9 | 18 | 7 | 11 | NA | NA | NA | NA | NA | No | NA |
| 6 | 5 | 85 | M | NA | 1020 | NA | NA | 167 | 0.9 | 30 | Death | – | Tandem left ICA MCA occlusion | NA | NA | 6 | Yes | NA | NA |
| 7 | 5 | 46 | M | NA | 60 | NA | NA | 178 | 0.9 | 5 | 18 | −13 | None | NA | NA | 5 | No | Contralateral M2 occlusion 30 hours after first IVT | NA |
| 8 | 6 | 78 | M | 220 | NA | NA | NA | NA | 0.6 | NA | 0 | 0 | NA | NA | NA | 0 | No | No | NA |
| 9 | 6 | 84 | M | 220 | NA | 79 | 41.6 | NA | 0.9 | 9 | 4 | 5 | NA | NA | 5 | NA | No | No | DAB 110 twice daily |
| 10 | 7 | 71 | F | 300 | NA | NA | 29 | 210 | 0.9 | 9 | NA | NA | NA | 0 | NA | 1 | No | No | DAB 150 twice daily |
| 11 | 8 | 76 | M | 220 | 210 | NA | 73.3 | 150 | 0.9 | 11 | 1 | 10 | None | NA | NA | NA | No | No | ↑to DAB 150 twice daily |
| 12 | 9 | 69 | M | 300 | NA | 74 | 39.2 | 197 | 0.9 | 12 | 1 | 11 | NA | 3 | NA | 3 | No | No | NA |
| 13 | 10 | 65 | F | NA | NA | NA | 31 | 210 | 0.9 | 19 | 1 | 18 | Left MCA (M1) | NA | NA | NA | NA | NA | NA |
| 14 | 11 | 75 | F | 300 | 90 | 74 | NA | 225 | 0.9 | 4 | 0 | 4 | None | NA | NA | NA | No | No | NA |
| 15 | 12 | 78 | F | 300 | 180 | 74 | NA | 210 | 0.9 | 4 | 0 | 4 | None | NA | NA | NA | NA | NA | NA |
| 16 | 13 | 75 | M | 220 | NA | NA | 39 | NA | 0.9 | 5 | 0 | 5 | NA | NA | NA | NA | No | No | ↑to DAB 150 twice daily |
| 17 | 14 | 75 | F | 220 | 570 | 90 | 35.5 | 120 | 0.9 | 7 | 18 | −11 | Left PCA | NA | NA | NA | No | Pneumonia | Another NOAC, ie, rivaroxaban after 3–4 weeks |
| 18 | 15 | 75 | M | 220 | NA | NA | 38 | 0.9 | 5 | 1 | 4 | NA | NA | 3 | 1 | No | NA | DAB 110 twice daily | |
| 19 | 15 | 40 | F | 220 | NA | NA | 24.3 | NA | 0.9 | 12 | 1 | 11 | NA | NA | 4 | 0 | No | NA | VKA |
| 20 | 15 | 83 | M | 220 | NA | NA | 34.6 | NA | 0.9 | 4 | 2 | 2 | NA | NA | 2 | 1 | No | NA | DAB 110 twice daily |
| 21 | 15 | 76 | M | 220 | NA | NA | 73 | NA | 0.9 | 11 | 1 | 10 | NA | NA | 4 | 1 | No | NA | ↑to DAB 150 twice daily |
| 22 | 15 | 67 | F | 300 | NA | NA | 26 | NA | 0.9 | 10 | 8 | 2 | NA | NA | 4 | 4 | No | NA | Apixaban 5 twice daily |
| 23 | 15 | 86 | F | 220 | NA | NA | 34.6 | NA | 0.9 | 5 | 2 | 3 | NA | NA | 2 | 1 | No | NA | DAB 110 twice daily |
| 24 | 15 | 86 | F | 220 | NA | NA | 45 | NA | 0.9 | 12 | 2 | 10 | NA | NA | 4 | 1 | No | NA | Edoxaban |
| 25 | 15 | 58 | F | 300 | NA | NA | 35.8 | NA | 0.9 | 3 | NA | NA | 3 | NA | No | NA | Argatroban | ||
| 26 | 15 | 53 | M | 300 | NA | NA | 25.9 | NA | 0.9 | 17 | Death | – | NA | NA | 5 | 6 | No | Pneumonia DVT, PE | NA |
| 27 | 15 | 75 | F | 220 | NA | NA | 35.6 | NA | 0.9 | 7 | 18 | −11 | NA | NA | 5 | 5 | No | NA | OAC not specified |
| 28 | 15 | 80 | M | 220 | NA | NA | 59 | NA | 0.9 | 5 | 2 | 3 | NA | NA | 2 | 0 | No | NA | DAB 110 twice daily |
| 29 | 15 | 94 | F | 220 | NA | NA | 69 | NA | 0.9 | 6 | 0 | 6 | NA | NA | 4 | 0 | No | NA | ↑to DAB 150 twice daily |
| 30 | 15 | 85 | M | 300 | NA | NA | 48 | NA | 0.9 | 7 | 1 | 6 | NA | NA | 3 | 1 | No | NA | DAB 150 twice daily |
| 31 | 15 | 78 | F | 220 | NA | NA | 84 | NA | 0.9 | 7 | 1 | 6 | NA | NA | 2 | 1 | No | NA | ↑to DAB 150 twice daily |
| 32 | 15 | 84 | F | 220 | NA | NA | 25.6 | NA | 0.9 | 14 | 14 | 0 | NA | NA | 4 | 4 | No | NA | ASA 100 |
| 33 | 15 | 77 | M | 220 | NA | NA | 43.6 | NA | 0.9 | 4 | 1 | 3 | NA | NA | 4 | 1 | No | NA | ↑to DAB 150 twice daily |
| 34 | 15 | 54 | M | 300 | NA | NA | 26.1 | NA | 0.9 | 11 | 2 | 9 | NA | NA | 3 | 2 | No | NA | DAB 150 twice daily |
| 35 | 15 | 89 | F | 220 | NA | NA | 38.9 | NA | 0.9 | 5 | 2 | 3 | NA | NA | 2 | 2 | No | NA | DAB 110 twice daily |
| 36 | 15 | 90 | F | 220 | NA | NA | 37 | NA | 0.9 | 7 | 3 | 4 | NA | NA | 3 | 1 | No | NA | DAB 110 twice daily |
| 37 | 16 | 68 | M | 220 | 45 | 34.1 | 34 | 110 | 0.9 | 3 | 3 | 0 | NA | NA | 3 | 2 | No | No | ↑to DAB 150 twice daily |
| 38 | 17 | 67 | F | 300 | 240 | NA | NA | 90 | 0.9 | 10 | NA | NA | Right MCA (M3) | NA | NA | NA | No | NA | NA |
| 39 | 18 | 76 | M | 220 | 540 | NA | 72.2 | 170 | 0.9 | 11 | 1 | 10 | None | NA | NA | NA | NA | No | NA |
| 40 | 19 | 71 | M | 300 | 109 | NA | 62 | 137 | 0.9 | 6 | 0 | 6 | NA | NA | NA | NA | No | No | NA |
| 41 | 20 | 66 | F | 300 | 200 | NA | 72 | 220 | 0.9 | 22 | 11 | 11 | NA | NA | NA | 4 | NA | No | NA |
| 42 | 20 | 63 | M | 220 | 165 | NA | 46 | 215 | 0.9 | 22 | 19 | 3 | NA | NA | NA | 6 | NA | Cerebral oedema | NA |
| 43 | 20 | 78 | F | 300 | 180 | NA | 44 | 185 | 0.9 | 20 | 16 | 4 | NA | NA | NA | 5 | Yes | NA | NA |
| 44 | 20 | 73 | F | 300 | 205 | NA | 61 | 208 | 0.9 | 6 | 3 | 3 | NA | NA | NA | 0 | NA | NA | NA |
| 45 | 20 | 52 | M | 300 | 273 | NA | 58 | 285 | 0.9 | 28 | 2 | 26 | NA | NA | NA | 3 | NA | NA | NA |
| 46 | 20 | 75 | M | 220 | 160 | NA | 45 | 165 | 0.9 | 6 | 0 | 6 | NA | NA | NA | 0 | NA | NA | NA |
| 47 | 21 | 85 | F | 220 | 255 | NA | 32.2 | 303 | 0.9 | 17 | 0 | 17 | No large vessel occlusion, several distal emboli | NA | NA | NA | No | No | DAB 110 twice daily |
| 48 | 22 | 78 | F | 300 | NA | NA | 49 | 125 | 0.9 | 11 | 0 | 11 | No large vessel occlusion | NA | NA | NA | No | No | DAB 150 twice daily |
| 49 | 23 | 79 | F | 220 | 120 | NA | 50.7 | 120 | 0.6 | 34 | 6 | 28 | NA | 4 | 5 | 4 | No | No | ↑to DAB 150 twice daily |
| 50 | 24 | 72 | M | 220 | 1050 | NA | 36.1 | 180 | 0.6 | 12 | 10 | 2 | NA | NA | NA | NA | No | No | No |
| 51 | 24 | 79 | M | 220 | 720 | NA | 24.6 | 173 | 0.6 | 12 | 12 | 0 | NA | NA | NA | 4 | No | No | Rivaroxaban 15 |
| 52 | 25 | 57 | M | 220 | NA | NA | 41.2 | 93 | 0.9 | 22 | 7 | 15 | Left MCA | 0 | 4 | 3 | No | Asymptomatic right popliteal artery occlusion | Rivaroxaban 15 |
| 53 | 26 | 74 | M | 220 | 145 | NA | NA | 135 | 0.9 | 16 | 0 | 16 | Right MCA (M1M2) | 0 | NA | 1 | Yes (asymptomatic) | No | Rivaroxaban 15 |
| 54 | Case 1 | 78 | M | 220 | 1200 | NA | 47 | 180 | 0.9 | 12 | 1 | 11 | None | 1 | 3 | 1 | No | No | Apixaban |
| 55 | Case 2 | 85 | M | 220 | 180 | NA | 53 | 250 | 0.9 | 22 | Death | – | Left MCA | 3 | 5 | 6 | Yes | HF, respiratory failure | NA |
| Overall (n=55) | 74.35 ± 11.32 | F 43.6% | 247.69 ± 38.43 | 344.19 ± 318.68 | 96.16 ± 61.16 | 46.68 ± 16.79 | 174.82 ± 53.76 | *Four had reduced rtPA | 11.26 ± 7.22 | 4.22 ± 5.71 | 6.33 ± 7.6 | 1.57 ± 1.72 | 3.52 ± 1.04 | 2.39 ± 2.03 | 3 sICH 1 aICH | ||||
aICH, asymptomatic intracerebral haemorrhage; aPTT, activated partial thromboplastin time; ASA, aspirin; DAB, dabigatran; DVT, deep vein thrombosis; HF, heart failure; ICA, internal carotid artery; ICH, intracerebral haemorrhage; IVT, intravenous thrombolysis; MCA, middle cerebral artery; mRS, modified Rankin Scale; N, patient consecutive number; NA, not applicable; NIHSS, National Institute of Health Stroke Scale; NOAC, non-vitamin K oral anticoagulant; PCA, posterior cerebral artery; PE, pulmonary embolism; rtPA, recombinant tissue plasminogen activator; sICH, symptomatic intracerebral haemorrhage; VKA, vitamin K antagonist.